A randomized, double-blind, parallell-group, controlled study of topical pentane-1,5-diol hydrogel in patients with impetigo
- Conditions
- Impetigo
- Registration Number
- EUCTR2005-000808-14-SE
- Lead Sponsor
- Ambria Dermatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
-Males and females; age 2 years or older
-Clinical diagnosis of impetigo
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
-Severe organic disease or other disease which may interfere with the administration or assessment of study medication such as severe immunodeficiency or tumor bearing disease; current use of drugs/preparations which may interfere with the study evaluation.
-Pregnant or lactating women or female patients without an ongoing efficient contraceptive method
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To determine whether topical pentane-1,5-diol hydrogel is efficacious in patients with impetigo.;Secondary Objective: -Reduction of impetigo<br>-Recurrence of impetigo within 1 week<br>;Primary end point(s): -Successfully treated cases with complete clinical improvement and no positive culture
- Secondary Outcome Measures
Name Time Method